PROFESSIONAL EDITION

The largest community of pharma leaders

Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board (CAB). Jeffrey Cummings, M.D., Sc.D., David Hosford M.D., Ph.D., Lon Schneider, M.D., M.S., and Pierre N. Tariot, M.D. join the CAB with deep and diverse experience in…..

 

 

http://www.businesswire.com/news/home/20190619005410/en/Cortexyme-Expands-Clinical-Advisory-Board-Key-Clinical/

Recent Articles